David Gilham PhD

Dr. David Gilham first joined Celyad in April 2016 as a member of the Scientific Advisory Board. As from September 1st, 2016, David became Vice-President R&D, heading the implementation of our Research and Development strategy for our programs in immuno-oncology. Dr. Gilham received his Ph.D. in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins. Prior to joining Celyad, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre.